Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting

The purpose of this study is to determine if patients with unexplained iron deficiency have underlying diseases processes such as celiac disease.

It is hypothesized that selectively screening patients with unexplained iron deficiency will reveal previously undiagnosed etiologies, including celiac disease and other causes of iron malabsorption along with various sources of occult GI blood loss.

Study Overview

• Status: Terminated
• Conditions: Celiac Disease; Iron Deficiency; Iron Malabsorption

Detailed Description

The primary purpose of the study is to document unexplained iron deficiency and its relationship to celiac disease, iron malabsorption and occult intestinal blood loss. Test results given to primary care physicians may prompt further testing for celiac disease (duodenal biopsy) or other potential causes of occult iron deficiency. The specific endpoints to be evaluated include:

• Prevalence of specific serum markers of celiac disease in those with unexplained serum markers of iron deficiency.
• Prevalence of iron malabsorption with and without celiac disease in the same population
• Frequency of other blood tests for malabsorption and their association with celiac disease or other cause of iron malabsorption.
• Frequency of specific historical markers associated with celiac disease
• Prevalence of unrecognized GI blood loss
• Quality of life improvement based on new diagnoses with appropriate therapy
• After one year follow-up, review patient records for additional diagnoses explaining iron deficiency.

Primary Objective:

Discover several etiologies of unexplained iron deficiency in a primary care clinic population including celiac disease, iron malabsorption and occult intestinal blood loss.

Secondary Objectives:

• Define percent of total clinic patient population with one or more markers of iron deficiency on last testing and the subset without an apparent etiology on their problem list ("study group").
• Define percent of patients in the study group that are currently iron deficient at time of study onset, and how many of those are actually anemic.
• Define percent of study group patients with iron malabsorption, with or without celiac disease.
• Document improved quality of life outcomes for those with new diagnoses and appropriate therapy, including celiac disease given gluten-free diet and iron therapy.
• For those patients identified with celiac disease, do statistical analysis of historical and lab parameters that are more highly linked to celiac disease to improve screening parameters.
• Document percent of various diagnoses that explain occult iron deficiency as found by primary care providers over the course of a one year follow-up after initial diagnosis. (Providers will be given all testing results related to their patients after the initial screening and at one year.)
• Specific cost-effectiveness of this screening procedure may be done in a future study if preliminary results are suggestive of improved outcomes.

• Study Type: Observational
• Enrollment (Actual): 13

Contacts and Locations

Study Locations

• United States
  • Washington
    • Spokane, Washington, United States, 99204
      • Providence Medical Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients from Providence Internal Medicine Clinic, Providence Internal Medicine Residency Services and Providence Family Medicine Residency Services

Description

Inclusion Criteria:

1. Active outpatients in the Providence Internal Medicine Residency Clinic, Family Medicine Residency Clinics, or Providence Internal Medicine Clinic
2. Demographic Age > 18 years. Diagnostic criteria: markers of iron deficiency at last check are defined as MCV<80 fL, Iron Sat<20% or ferritin<30 ng/mL.
3. Patient signs informed consent document and HIPAA authorization for release of personal health information.
4. Ability to understand procedures and comply with them for one year duration of study

Exclusion Criteria:

1. Any documented significant acute or chronic blood loss, per medical record review or self- report (see Appendix B). Significant blood loss includes

   1. Acute blood loss requiring iron treatment or transfusions within 1 year prior to the above measure of iron deficiency
   2. Chronic blood loss (such as menorrhagia, GI bleeding, hemoptysis, hematuria, chronic nose bleeds, hemolysis, regular blood donations, or major trauma requiring transfusion or iron therapy)
   3. Thalassemia or other major hemolytic diseases.
2. Prior diagnosis of celiac disease, or other documented cause of iron malabsorption.
3. Women who are currently pregnant, or who were pregnant with 6 months prior to time of last testing.
4. Those currently or recently on chemotherapy (within the last 6 months)
5. Those with prior gastric resection or bariatric surgery
6. Those with advanced chronic kidney disease (stage 4 or 5)
7. Any other reasons that, in the investigators' opinion, may prevent compliance with protocol

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Positive results for Expanded Celiac Disease Panel	Expanded Celiac Disease Panel includes TTG-IgG, TTG-IgA, AntiGliadin-IgG, AngtiGliadin-IgA, and Total Serum IgA	Upon consent and enrollment in the study, laboratory tests will be done to evaluate for the presence of Celiac Disease

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Clinic Patient Population with one or more markers of iron deficiency	Other tests will be done at enrollment to assess for iron malabsorption and possibly to identify causes of iron malabsorption other than celiac disease. These include Iron absorption Testing (serum iron level before and after oral FeSO4 tablet or liquid), with percent iron saturation. Ferritin, Hemoglobin and Hematocrit, Vitamin D level, Folate, Vitamin B12 level, Aspartate Aminotransferase (AST), and Stool Occult Blood Test	at enrollment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improved Quality of Life after one year of intervention (either gluten-free diet if Celiac disease is diagnosed and/or recommendation of daily iron supplementation)	For patients diagnosed with Celiac disease at enrollment, a gluten-free diet will be advised explained by a Registered Dietician. Patients not diagnosed with celiac disease but with iron deficiency or malabsorption will be advised to take daily oral iron supplements. Quality of Life Surveys will be administered at enrollment and at the end of one year to assess for improvement resulting from diet and/or supplementation.	Enrollment and End of One Year

Collaborators and Investigators

• Sponsor: Providence Medical Research Center
• Collaborators: Providence Sacred Heart Medical Center & Children's Hospital
• Investigators: Principal Investigator: Samuel Palpant, MD, Providence Internal Medicine Residency Services

Study record dates

Study Major Dates

• Study Start: March 1, 2014
• Primary Completion (Actual): January 1, 2015
• Study Completion (Actual): January 1, 2015

Study Registration Dates

• First Submitted: January 13, 2014
• First Submitted That Met QC Criteria: January 13, 2014
• First Posted (Estimate): January 15, 2014

Study Record Updates

• Last Update Posted (Estimate): April 5, 2016
• Last Update Submitted That Met QC Criteria: April 1, 2016
• Last Verified: April 1, 2016

More Information

Terms related to this study

• Keywords: Celiac Disease; Iron-Deficiency Anemia; Celiac Sprue
• Additional Relevant MeSH Terms: Digestive System Diseases; Metabolic Diseases; Hematologic Diseases; Gastrointestinal Diseases; Intestinal Diseases; Anemia, Hypochromic; Anemia; Iron Metabolism Disorders; Anemia, Iron-Deficiency; Celiac Disease; Malabsorption Syndromes
• Other Study ID Numbers: PMRC-1909-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO